Clinical trials: Cancer: Solid Tumors
Advanced Solid Tumors
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose…
- Trial name
- NCT02122770
- Testing
- MLN4924, Fluconazole, Itraconazole
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Neoplasms, Brain
A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
This was a 2-part, Phase I/IIa, multi-center, open label, study in pediatric and adolescent patients with advanced BRAF V600 mutation-positive solid tumors.
- Trial name
- NCT01677741
- Testing
- Dabrafenib
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Advanced Solid Tumors
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.
- Trial name
- NCT06459973
- Testing
- intravenous (IV) infusion
- Where
- 43 sites in United States, China
- Volunteers
- 252 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Malignant Solid Tumor
A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.
This is a Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.
- Trial name
- NCT05396339
- Testing
- IAE0972
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Advanced Solid Tumors
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
The purpose of the study is to determine whether amrubicin is safe and effective in the treatment of patients with advanced solid tumors.
- Trial name
- NCT00915083
- Testing
- Amrubicin
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Celgene
HER2 Expressing Solid Tumours
Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers
The purpose of this study is to determine the safety profile and maximum tolerable dose (MTD) of GBR 1302 monotherapy in subjects with HER2 positive cancers
- Trial name
- GBR 1302-101 (NCT02829372)
- Testing
- CD3/HER2 bispecific monoclonal antibody
- Where
- 8 sites in United States, Germany
- Volunteers
- 36 people
- Sponsor
- Ichnos Sciences SA
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05393427
- Testing
- BL-B01D1
- Where
- 4 sites in China
- Volunteers
- 4 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Solid Tumor, Adult, Impaired Liver Function
Oral Docetaxel in Patients With Normal or Impaired Liver Function
This is an open label, single centre pharmacological and safety study to define the safety and pharmacokinetics of ModraDoc006/r in a weekly dosing schedule in patients with impaired liver function who might have benefit from a…
- Trial name
- NCT05084456
- Testing
- ModraDoc006/r
- Where
- Netherlands
- Sponsor
- Modra Pharmaceuticals
Advanced Solid Tumor
Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
This is a first-in-human, Phase I/II, open-label, multi-centre, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of LM-108 as a single agent or in…
- Trial name
- NCT05199753
- Testing
- LM-108, An Anti-PD-1 Antibody
- Where
- 6 sites in Australia
- Volunteers
- 78 people
- Sponsor
- LaNova Australia Pty Limited
Advanced Solid Malignancies
A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid…
- Trial name
- NCT02575651
- Testing
- Fluzoparib
- Where
- 2 sites in China
- Volunteers
- 79 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Bladder Cancer, Pancreas Cancer
A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
This multicenter, non-randomized, Phase II study will assess the efficacy, safety, and pharmacokinetics of trastuzumab emtansine in participants with HER2 overexpressing locally advanced (unresectable and not treatable with…
- Conditions
- Bladder Cancer, Pancreas Cancer, Cholangiocellular Carcinoma
- Trial name
- KAMELEON (NCT02999672)
- Testing
- Trastuzumab Emtansine
- Where
- 16 sites in Italy, Netherlands and 2 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Gastric Cancer
IKS014 in Advanced Solid Tumors That Express HER2
This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate…
- Conditions
- Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
- Trial name
- NCT05872295
- Testing
- IKS014
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 165 people
- Sponsor
- Iksuda Therapeutics Ltd.
Advanced Solid Tumors
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-3802 monotherapy in patients with malignant solid tumors.
- Trial name
- NCT06770569
- Testing
- HRS-3802
- Where
- 6 sites in Australia, China
- Volunteers
- 100 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Solid Tumor, Lymphoma, Malignant
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
The purpose of this study is to assess the pharmacokinetics (PK) of enzastaurin and its metabolites in native Chinese participants with advanced and/or metastatic solid tumors or lymphoma.
- Trial name
- NCT01432951
- Testing
- Enzastaurin
- Where
- 3 sites in China
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07349537
- Testing
- RMC-5127, daraxonrasib, cetuximab
- Where
- 9 sites in United States
- Volunteers
- 574 people
- Sponsor
- Revolution Medicines, Inc.
Solid Tumor
A Study of LY3200882 in Participants With Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.
- Trial name
- NCT02937272
- Testing
- LY3200882, LY3300054, Gemcitabine
- Where
- 18 sites in United States, Australia and 6 more
- Volunteers
- 223 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Adult
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in…
- Trial name
- NCT06026254
- Testing
- IMSA101, Immune Checkpoint Inhibitor
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- ImmuneSensor Therapeutics Inc.
PROC, Platinum Resistant Ovarian Cancer
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors.
- Conditions
- PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT07470853
- Testing
- HWK-016, MUCIN-16-targeted ADC, Bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 265 people
- Sponsor
- Whitehawk Therapeutics, Inc.
Malignant Neoplasm
A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced Cancer
NBM-BMX is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by NatureWise. NBM-BMX is a histone deacetylase (HDAC) inhibitor and has been shown to be particularly active against HDAC8.
- Trial name
- NCT03726294
- Testing
- NBM-BMX softgel capsules
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- NatureWise Biotech & Medicals Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.